A Population-Based Study of Men With Low-Volume Low-Risk Prostate Cancer: Does African-American Race Predict for More Aggressive Disease?

Schreiber, David; Chhabra, Arpit; Rineer, Justin; Weedon, Jeremy; Schwartz, David L.

doi:10.1016/j.clgc.2015.02.006

Cited by 23 publications

(16 citation statements)

References 28 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…82,83 More representative sampling could possibly be achieved using technologies such as MRI-guided fusion biopsy. 66 Regardless, Schreiber and colleagues did not observe a statistically significant increase in rates of adverse pathology among AA men (OR 1.43, p=0.16) using the SEER cohort, 84 and it is possible that race-specific data are still too preliminary to trigger changes in practice. 76 Ultimately, AS may be a reasonable option for some AA men, but currently utilized AS criteria appear to perform poorly in the AA population.…”

Section: As In Specific Patient Subgroupsmentioning

confidence: 95%

Active surveillance for prostate cancer: current evidence and contemporary state of practice

et al. 2016

View full text Add to dashboard Cite

Prostate cancer remains among the most commonly diagnosed malignancies worldwide. Early diagnosis and curative treatment appear to improve survival in men with unfavorable-risk cancers, but significant concerns exist regarding the overdiagnosis and overtreatment of men with lower-risk cancers. To this end, active surveillance (AS) has emerged as a primary management strategy in men with favorable-risk disease, and contemporary data suggest that use of AS has increased worldwide. Although published surveillance cohorts differ by protocol, reported rates of metastatic disease and prostate cancer-specific mortality are exceedingly low in the intermediate term (5–10 years). Such outcomes appear to be closely associated with program-specific criteria for selection, monitoring, and intervention, suggesting that AS – like other management strategies – could be individualized based on the level of risk acceptable to patients in light of personal preferences. Additional data are needed to better establish the risks associated with AS and to identify patient-specific characteristics that could modify prognosis.

show abstract

Section: As In Specific Patient Subgroupsmentioning

confidence: 95%

Active surveillance for prostate cancer: current evidence and contemporary state of practice

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Although the current coding schema is valuable within the context of quality improvement, the current study demonstrated a low level of interclass validation for the code values of 997, 998, and 999. A comparison of PSA [19][20][21][22][23] Therefore, the difference between observations that would have been excluded before PSA validation review but retained after the review is within the range of 1%, which is significantly less than the 5.09% of cases reported in Table 1 to require corrections in PSA unknown codes. SEER data from 2012 demonstrated that the meaningful error rate for PSA coding at the time of diagnosis was 5.81% overall.…”

Section: Discussionmentioning

confidence: 92%

“…Meanwhile, the estimate of cases with an unknown PSA value decreased after PSA review, from 2221 (4.42%) to 1727 (3.43%). Investigators often exclude observations with unknown PSA values from prostate cancer analyses 19, 20, 21, 22, 23. Therefore, the difference between observations that would have been excluded before PSA validation review but retained after the review is within the range of 1%, which is significantly less than the 5.09% of cases reported in Table 1 to require corrections in PSA unknown codes.…”

Section: Discussionmentioning

confidence: 99%

Validation of prostate‐specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries

Adamo

Boten

Coyle

et al. 2016

Cancer

View full text Add to dashboard Cite

BACKGROUNDResearchers have used prostate‐specific antigen (PSA) values collected by central cancer registries to evaluate tumors for potential aggressive clinical disease. An independent study collecting PSA values suggested a high error rate (18%) related to implied decimal points. To evaluate the error rate in the Surveillance, Epidemiology, and End Results (SEER) program, a comprehensive review of PSA values recorded across all SEER registries was performed.METHODSConsolidated PSA values for eligible prostate cancer cases in SEER registries were reviewed and compared with text documentation from abstracted records. Four types of classification errors were identified: implied decimal point errors, abstraction or coding implementation errors, nonsignificant errors, and changes related to “unknown” values.RESULTSA total of 50,277 prostate cancer cases diagnosed in 2012 were reviewed. Approximately 94.15% of cases did not have meaningful changes (85.85% correct, 5.58% with a nonsignificant change of <1 ng/mL, and 2.80% with no clinical change). Approximately 5.70% of cases had meaningful changes (1.93% due to implied decimal point errors, 1.54% due to abstract or coding errors, and 2.23% due to errors related to unknown categories). Only 419 of the original 50,277 cases (0.83%) resulted in a change in disease stage due to a corrected PSA value.CONCLUSIONSThe implied decimal error rate was only 1.93% of all cases in the current validation study, with a meaningful error rate of 5.81%. The reasons for the lower error rate in SEER are likely due to ongoing and rigorous quality control and visual editing processes by the central registries. The SEER program currently is reviewing and correcting PSA values back to 2004 and will re‐release these data in the public use research file. Cancer 2017;123:697–703. © 2016 American Cancer Society.

show abstract

“…On the other hand, in a large population‐based study of patients with low‐risk low‐volume prostate cancer, it was reported that A‐A men were no more likely to have pathologically aggressive features than Caucasian men . In recent years, A‐A men have experienced greater improvement in prostate cancer survival, and the racial difference has decreased .…”

Section: Discussionmentioning

confidence: 99%

Detection of prostate cancer using magnetic resonance imaging/ultrasonography image‐fusion targeted biopsy in African‐American men

et al. 2017

View full text Add to dashboard Cite

show abstract

A Population-Based Study of Men With Low-Volume Low-Risk Prostate Cancer: Does African-American Race Predict for More Aggressive Disease?

Cited by 23 publications

References 28 publications

Active surveillance for prostate cancer: current evidence and contemporary state of practice

Active surveillance for prostate cancer: current evidence and contemporary state of practice

Validation of prostate‐specific antigen laboratory values recorded in Surveillance, Epidemiology, and End Results registries

Detection of prostate cancer using magnetic resonance imaging/ultrasonography image‐fusion targeted biopsy in African‐American men

Contact Info

Product

Resources

About